Last reviewed · How we verify
Allo-RevCAR01-T
At a glance
| Generic name | Allo-RevCAR01-T |
|---|---|
| Also known as | Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment |
| Sponsor | AvenCell Europe GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
- Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allo-RevCAR01-T CI brief — competitive landscape report
- Allo-RevCAR01-T updates RSS · CI watch RSS
- AvenCell Europe GmbH portfolio CI